Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 266

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 266
---
. 11 to approve the composition of the new senior management following the Merger. •Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •Proposal No. 12.2 to approve the compensation for the executive officers. 105 •Proposal No. 13 to approve the CVR Agreement. •Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. The following proposals require a Supermajority Vote at the NLS Meeting: •Proposal No. 2 to approve the par value reduction, reverse split and ordinary share capital increase with contribution of the Kadimastem shares to implement the Merger. •Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of NLS Preferred Shares. •Proposal No. 4 to approve the implementation of capital band (Art. 3a). •Proposal No. 5 to approve the conditional share capital for employee and advisory options (Art. 3b). •Proposal No. 6 to approve the conditional share capital for shareholders’ options (Art. 3c). •Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. Voting Your Shares Shareholders can either vote by personal participation or by representation. All shareholders attending the NLS Meeting (either by personal participation or representation) are requested to complete and sign the registration form, attached as an exhibit to this proxy statement/prospectus and the invitation to the NLS Meeting, latest until September 25, 2025 (received by 11:59 pm CET) and send it either via postal mail (NLS Pharmaceutics Ltd., Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com) to NLS. In the event that you do not intend to participate personally in the NLS Meeting, you may be represented by the independent proxy, KBT Treuhand AG Zürich, Kreuzplatz5, 8032 Zurich, Switzerland or a third party (who need not be a shareholder) by completing and signing the respective power of attorney (proxy card). The independent proxy will be physically present at NLS Meeting to vote on behalf of the shareholders who issued instructions to him. If the independent proxy cannot be present, the NLS Board will appoint a new independent proxy. The powers of attorney granted to the independent proxy will also be valid for any new independent